Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP-HFpEF

Novo Nordisk · Phase 3 · Completed · Enrollment 529

NCT04788511

EudraCT 2019-004452-11

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

≥5%
34.190.5
≥10%
56.197.9
≥15%
76.499.6
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutiden/r34.1%56.1%76.4%
Placebo (semaglutide)n/r90.5%97.9%99.6%

Not shown

Every selected arm is drawn.